BMY logo Bristol-Myers Squibb Company +
Bristol-Myers Squibb Company
+

Bristol-Myers Squibb Company (BMY) Business News

Track Bristol-Myers Squibb Company in real time with a live news feed covering Bristol-Myers Squibb Company stock news, official press releases, company announcements, and an archive of historical Bristol-Myers Squibb Company news. ...more

  • Calendar
    Years
    Get instant access
    Sign up for free
    Get instant access
    Sign up for free
    Month
    Jan
    Feb
    Mar
    Apr
    May
    Jun
    Jul
    Aug
    Sep
    Oct
    Nov
    Dec
    Date
    Su
    Mo
    Tu
    We
    Th
    Fr
    Sa
    Selected Filter
    No selection
11:00 AM | Saturday | Aug 29, 2026 Business Wire

Bristol Myers Squibb Presents Data Up to Five Years Reinforcing the Long-Term Efficacy and Safety of Camzyos (mavacamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) at the European Society of Cardiology (ESC) Congress 2026

News Thumbnail
9:00 AM | Thursday | Aug 20, 2026 Business Wire

Chai Discovery Announces Collaboration with Bristol Myers Squibb to Advance AI-Driven Antibody Discovery

News Thumbnail
8:00 AM | Thursday | Aug 13, 2026 PRNewsWire

Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration

News Thumbnail
9:01 AM | Monday | Aug 10, 2026 Business Wire

Bristol Myers Squibb Advances U.S. Manufacturing Investment with New $2.3 Billion Campus in Houston, Texas

News Thumbnail
8:30 AM | Wednesday | Aug 5, 2026 Business Wire

Schrödinger Announces Strategic Collaboration and Software Agreement with Bristol Myers Squibb to Deploy AI Co-Scientist Bunsen for Agentic Drug Discovery

News Thumbnail
6:59 AM | Monday | Jul 20, 2026 Business Wire

Bristol Myers Squibb to Build the Most Powerful AI Factory in Life Sciences with NVIDIA

News Thumbnail
6:59 AM | Monday | Jul 13, 2026 Business Wire

U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma

News Thumbnail
6:59 AM | Thursday | Jun 18, 2026 Business Wire

Bristol Myers Squibb to Report Results for Second Quarter 2026 on July 30, 2026

News Thumbnail
6:59 AM | Monday | Jun 8, 2026 Business Wire

Mariska Hargitay Partners with Bristol Myers Squibb for “Investigating Myeloma” Awareness Campaign to Honor Her Father 20 Years After Losing Him to the Disease

News Thumbnail

Bristol Myers Squibb Presents Data Up to Five Years Reinforcing the Long-Term Efficacy and Safety of Camzyos (mavacamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) at the European Society of Cardiology (ESC) Congress 2026

Business Wire

11:00 AM | Saturday | Aug 29, 2026

news photo
Loading...

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Camzyos--Bristol Myers Squibb Presents Data Up to Five Years Reinforcing the Long-Term Efficacy and Safety of Camzyos (mavacamten).

Read full article redirect
11:00 AM | Saturday | Aug 29, 2026

Bristol Myers Squibb Presents Data Up to Five Years Reinforcing the Long-Term Efficacy and Safety of Camzyos (mavacamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) at the European Society of Cardiology (ESC) Congress 2026

Business Wire

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Camzyos--Bristol Myers Squibb Presents Data Up to Five Years Reinforcing the Long-Term Efficacy and Safety of Camzyos (mavacamten).

Read full article arrow
News Thumbnail
9:00 AM | Thursday | Aug 20, 2026

Chai Discovery Announces Collaboration with Bristol Myers Squibb to Advance AI-Driven Antibody Discovery

Business Wire

SAN FRANCISCO--(BUSINESS WIRE)--Chai Discovery Announces Collaboration with Bristol Myers Squibb to Advance AI-Driven Antibody Discovery.

Read full article arrow
News Thumbnail
8:00 AM | Thursday | Aug 13, 2026

Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration

PRNewsWire

SAN DIEGO, Aug. 13, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) ("Atrium," "Atrium Therapeutics" or the "Company"), a biopharmaceutical company dedicated to delivering RNA therapeutics to the heart, today announced it has earned another $15 million milestone payment from Bristol Myers Squibb (NYSE: BMY) based on the successful delivery of a lead compound targeting an undisclosed cardiology indication under the Company's ongoing collaboration. "Atrium's vision is to deliver treatments that address the underlying cause of serious heart disease, including rare genetic cardiomyopathies," said Kathleen Gallagher, President and CEO of Atrium Therapeutics.

Read full article arrow
News Thumbnail
9:01 AM | Monday | Aug 10, 2026

Bristol Myers Squibb Advances U.S. Manufacturing Investment with New $2.3 Billion Campus in Houston, Texas

Business Wire

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--Bristol Myers Squibb Advances U.S. Manufacturing Investment with New $2.
3 Billion Campus in Houston, Texas.

Read full article arrow
News Thumbnail
8:30 AM | Wednesday | Aug 5, 2026

Schrödinger Announces Strategic Collaboration and Software Agreement with Bristol Myers Squibb to Deploy AI Co-Scientist Bunsen for Agentic Drug Discovery

Business Wire

NEW YORK--(BUSINESS WIRE)-- #AgenticAI--Schrödinger, Inc. announced a strategic agreement with BMS to deploy Bunsen, Schrödinger's agentic AI co-scientist, within its research organization.

Read full article arrow
News Thumbnail
6:59 AM | Monday | Jul 20, 2026

Bristol Myers Squibb to Build the Most Powerful AI Factory in Life Sciences with NVIDIA

Business Wire

PRINCETON, N.J.--(BUSINESS WIRE)---- $bmy--Bristol Myers Squibb to Build the Most Powerful AI Factory in Life Sciences with NVIDIA.

Read full article arrow
News Thumbnail
6:59 AM | Monday | Jul 13, 2026

U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma

Business Wire

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--U.S. FDA Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma.

Read full article arrow
News Thumbnail
6:59 AM | Thursday | Jun 18, 2026

Bristol Myers Squibb to Report Results for Second Quarter 2026 on July 30, 2026

Business Wire

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb to Report Results for Second Quarter 2026 on July 30, 2026.

Read full article arrow
News Thumbnail
6:59 AM | Monday | Jun 8, 2026

Mariska Hargitay Partners with Bristol Myers Squibb for “Investigating Myeloma” Awareness Campaign to Honor Her Father 20 Years After Losing Him to the Disease

Business Wire

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMY--Mariska Hargitay Partners with BMS for “Investigating Myeloma” Awareness Campaign to Honor Her Father 20 Years After Losing Him to the Disease.

Read full article arrow
News Thumbnail